Boston Scientific Corp Stock Revenue
BSX Stock | USD 68.49 0.13 0.19% |
Boston Scientific Corp fundamentals help investors to digest information that contributes to Boston Scientific's financial success or failures. It also enables traders to predict the movement of Boston Stock. The fundamental analysis module provides a way to measure Boston Scientific's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Boston Scientific stock.
At this time, Boston Scientific's Current Deferred Revenue is fairly stable compared to the past year. Total Revenue is likely to rise to about 15 B in 2024, whereas Ebit Per Revenue is likely to drop 0.10 in 2024. Boston | Revenue |
Boston Revenue Analysis
Boston Scientific's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
More About Revenue | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 9.5B | 9.3B | 9.5B | 10.0B | Total Assets | 32.2B | 32.5B | 35.1B | 36.9B |
Revenue | = | Money Received | - | Discounts and Returns |
Current Boston Scientific Revenue | 14.24 B |
Most of Boston Scientific's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Boston Scientific Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Boston
Projected quarterly revenue analysis of Boston Scientific Corp provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Boston Scientific match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Boston Scientific's stock price.
Boston Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Boston Scientific is extremely important. It helps to project a fair market value of Boston Stock properly, considering its historical fundamentals such as Revenue. Since Boston Scientific's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Boston Scientific's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Boston Scientific's interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition |
Boston Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Boston Scientific Corp reported 14.24 B of revenue. This is 86.71% higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 50.93% lower than that of the firm.
Boston Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boston Scientific's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boston Scientific could also be used in its relative valuation, which is a method of valuing Boston Scientific by comparing valuation metrics of similar companies.Boston Scientific is currently under evaluation in revenue category among related companies.
Boston Scientific ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Boston Scientific's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Boston Scientific's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Boston Scientific Institutional Holders
Institutional Holdings refers to the ownership stake in Boston Scientific that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Boston Scientific's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Boston Scientific's value.Shares | Bollard Group Llc | 2023-12-31 | 22.4 M | Citadel Advisors Llc | 2023-09-30 | 21.2 M | Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main | 2023-12-31 | 21.1 M | Hhg Plc | 2023-12-31 | 19.5 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 18.8 M | Artisan Partners Limited Partnership | 2023-12-31 | 17.2 M | Bank Of New York Mellon Corp | 2023-12-31 | 17 M | Norges Bank | 2023-12-31 | 16.1 M | Northern Trust Corp | 2023-12-31 | 13.7 M | Fmr Inc | 2023-12-31 | 138.3 M | Blackrock Inc | 2023-12-31 | 126.6 M |
Boston Fundamentals
Return On Equity | 0.0858 | ||||
Return On Asset | 0.0447 | ||||
Profit Margin | 0.11 % | ||||
Operating Margin | 0.17 % | ||||
Current Valuation | 109.49 B | ||||
Shares Outstanding | 1.47 B | ||||
Shares Owned By Insiders | 0.19 % | ||||
Shares Owned By Institutions | 93.60 % | ||||
Number Of Shares Shorted | 11.48 M | ||||
Price To Earning | 107.05 X | ||||
Price To Book | 5.23 X | ||||
Price To Sales | 7.08 X | ||||
Revenue | 14.24 B | ||||
Gross Profit | 8.68 B | ||||
EBITDA | 3.62 B | ||||
Net Income | 1.59 B | ||||
Cash And Equivalents | 928 M | ||||
Cash Per Share | 0.24 X | ||||
Total Debt | 9.49 B | ||||
Debt To Equity | 0.51 % | ||||
Current Ratio | 1.45 X | ||||
Book Value Per Share | 13.15 X | ||||
Cash Flow From Operations | 2.5 B | ||||
Short Ratio | 1.75 X | ||||
Earnings Per Share | 1.07 X | ||||
Price To Earnings To Growth | 1.81 X | ||||
Target Price | 71.96 | ||||
Number Of Employees | 48 K | ||||
Beta | 0.78 | ||||
Market Capitalization | 100.86 B | ||||
Total Asset | 35.14 B | ||||
Retained Earnings | 819 M | ||||
Working Capital | 1.58 B | ||||
Current Asset | 1.21 B | ||||
Current Liabilities | 923 M | ||||
Z Score | 7.21 | ||||
Net Asset | 35.14 B |
About Boston Scientific Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Boston Scientific Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boston Scientific using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boston Scientific Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Current Deferred Revenue | 266 M | 333.1 M | |
Total Revenue | 14.2 B | 15 B | |
Cost Of Revenue | 4.3 B | 4.6 B | |
Ebit Per Revenue | 0.16 | 0.10 |
Pair Trading with Boston Scientific
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Boston Scientific position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Boston Scientific will appreciate offsetting losses from the drop in the long position's value.Moving together with Boston Stock
0.62 | COO | Cooper Companies Financial Report 6th of June 2024 | PairCorr |
Moving against Boston Stock
0.89 | PHG | Koninklijke Philips Financial Report 22nd of April 2024 | PairCorr |
0.87 | PIIIW | P3 Health Partners | PairCorr |
0.82 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.81 | MASS | 908 Devices Financial Report 14th of May 2024 | PairCorr |
0.77 | NEOG | Neogen Report 4th of April 2024 | PairCorr |
The ability to find closely correlated positions to Boston Scientific could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Boston Scientific when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Boston Scientific - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Boston Scientific Corp to buy it.
The correlation of Boston Scientific is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Boston Scientific moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Boston Scientific Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Boston Scientific can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Boston Scientific Piotroski F Score and Boston Scientific Altman Z Score analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Boston Stock analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Boston Scientific's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boston Scientific. If investors know Boston will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boston Scientific listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.856 | Earnings Share 1.07 | Revenue Per Share 9.8 | Quarterly Revenue Growth 0.149 | Return On Assets 0.0447 |
The market value of Boston Scientific Corp is measured differently than its book value, which is the value of Boston that is recorded on the company's balance sheet. Investors also form their own opinion of Boston Scientific's value that differs from its market value or its book value, called intrinsic value, which is Boston Scientific's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boston Scientific's market value can be influenced by many factors that don't directly affect Boston Scientific's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boston Scientific's value and its price as these two are different measures arrived at by different means. Investors typically determine if Boston Scientific is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boston Scientific's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.